Communications Biology:前列腺癌患者中,FOXA1非翻译区变异频率研究

2018-09-05 AlexYang MedSci原创

前列腺癌具有低的体细胞变异速率,但是非编码区仍旧还未有研究阐释。最近,有研究人员对72个已知的前列腺癌驱使基因的非翻译区进行了测序研究。研究包括了428名患有转移性前列腺癌的患者。研究人员在12%的患者中鉴定了FOXA 3'-UTR变异。这些变异中主要是插入和缺失,覆盖了整个UTR,并且没有基序富集,并且在其他的癌症中没有检测到。FOXA1处于雄激素调节的非编码基因AL121790.1的正面方向,

前列腺癌具有低的体细胞变异速率,但是非编码区仍旧还未有研究阐释。最近,有研究人员对72个已知的前列腺癌驱使基因的非翻译区进行了测序研究。

研究包括了428名患有转移性前列腺癌的患者。研究人员在12%的患者中鉴定了FOXA 3'-UTR变异。这些变异中主要是插入和缺失,覆盖了整个UTR,并且没有基序富集,并且在其他的癌症中没有检测到。FOXA1处于雄激素调节的非编码基因AL121790.1的正面方向,导致了强烈的前列腺特异性双向转录,并跨过了FOXA1基因的3'-UTR。这也表明了转录活性是局部超变异的一个原因。另外,体细胞变异的插入优势模式能够扩展到FOXA1编码区域,并通过克隆选择在叉头区域产生非移码变异插入簇。

最后,研究人员指出,在高频率和谱系特异性情况下,体细胞FOXA1 3'-UTR变异可能对诊断和筛选方法是有用的,

原始出处:

Matti Annala, Sinja Taavitsainen, Gillian Vandekerkhove et al. Frequent mutation of the FOXA1untranslated region in prostate cancer. Communications Biology. 24 Aug 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2019-08-03 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2019-07-29 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2018-09-07 ylzr123

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2087416, encodeId=aa51208e41658, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Aug 03 04:01:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016019, encodeId=abdd201601967, content=<a href='/topic/show?id=c0f0e62021' target=_blank style='color:#2F92EE;'>#FOXA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7620, encryptionId=c0f0e62021, topicName=FOXA1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jan 16 07:01:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918274, encodeId=905f19182e4a9, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 03:01:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739999, encodeId=b8401e3999969, content=<a href='/topic/show?id=376138119e4' target=_blank style='color:#2F92EE;'>#变异频率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38119, encryptionId=376138119e4, topicName=变异频率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3abf34619649, createdName=ms7474195563676018, createdTime=Tue Sep 11 02:01:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767510, encodeId=245d1e6751072, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jan 17 01:01:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343431, encodeId=91a6343431a5, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 07 12:45:38 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342510, encodeId=6b5d1342510df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 07 11:01:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]

相关资讯

Prostate Cancer P D:前列腺癌诊断后自杀的发生率和风险因子

是否前列腺癌的诊断在男性中造成心理压力从而引起自杀,仍旧存在争议。最近,有研究人员对之前的研究进行了元分析来调查前列腺癌诊断男性的自杀的发生率和相关的风险因子。研究发现,8个观察性研究总共包括了1281393名诊断为前列腺癌的男性,并且包括了842294名匹配的无前列腺癌的男性对照。在前列腺癌诊断的第一年,总的增加的自杀相对风险(RR)为2.01(95% CI: 1.52-2.64; P<0

前列腺癌筛查对总死亡率没有改变?国人要不要做

我国前列腺癌发病和死亡率,兼具发达与不发达国家的特点,用以提高生存率、降低死亡率的筛查该如何进行,成为近年来最具争议的话题之一。

Oncogene:miR-96和RARγ信号途径能够调控雄激素信号和前列腺癌恶化

在前列腺癌(PCa)中,视黄酸受体γ(NR1B3/RARG编码RARγ)的表达通常是减少的。因此,有研究人员探究了RARγ表达减少后的细胞学和基因调控结果,并且确定了RARγ调控机制。在非恶性(RWPE-1和HPr1-AR)和恶性(LNCaP)前列腺模型中,RARG shRNA方法能够减少RARγ水平;且RARγ水平的减少,而不是添加外源维甲酸,能够对前列腺细胞的存活和基因的表达产生最大的影响。C

Urol J:巨噬细胞抑制因子-173基因多样性与前列腺癌生物学行为相关性研究

慢性炎症是前列腺癌病因学的一个重要因子。巨噬细胞游走抑制因子(MIF)在炎症响应方面具有重要的调节作用。最近,有研究人员调查了MIF-173G/C多样性与前列腺癌发生和生物学行为之间潜在相关性。研究人员在128名前列腺癌受试者和135名对照中利用PCR-RELP技术对MIF的多样性进行了分析。研究发现,MIF-173*C等位基因的频率在前列腺癌患者(19.5%)中要比健康对照个体(10%)显著更高

Urol Oncol:前列腺癌致瘤过程中,类转酮醇酶1(TKTL1)的表达改变

前列腺癌(CaP)是老年男性中常见的非上皮癌症。由于前列腺癌的异质性和临床结果和治疗响应的高度可变性,泌尿学家对该疾病的控制仍旧是一个挑战。最近,有研究人员评估了类转酮醇酶1(TKTL1)在良性前列腺组织、瘤旁组织和CaP(疾病不同阶段)中的表达,并评估了与临床病理发现的关系,从而检测TKTL1的表达是否与CaP致瘤过程相关。研究总共包括了100个组织样本。研究发下,TKTL1蛋白的表达模式在良性

Sci Rep:在前列腺癌细胞中,突变等位基因的定量研究阐释了TP53促使去势抵抗性的遗传基础

关于人类癌症的本质是遗传疾病,并通过基因变异引起的观点已经有了很详细的阐释,然而在癌症基因的功能研究中,上述观点还没有进行过很好的探索。最近,有研究人员在一个异源群体中,描述了一个简单的基于遗传的方法来快速和灵敏的阐释感兴趣的基因的变异对其宿主细胞的命运的影响,从而监控与致瘤相关的遗传选择。研究人员利用他们的方法,发现了TP53功能的缺失能够通过瞬间增强不依赖雄激素细胞的生长和促使基因组不稳定性的